Total Funding
22
57
Total FundingVenture - Series Unknown raised
Growth Score
-3 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
30163
Concarlo Therapeutics is a preclinical-stage oncology company developing transformative therapeutics to target drug-resistant cancers.
- Arthur Klausner: Executive Chairman
- Jason Mraz: Co-Founder & President
About the Company
Concarlo Therapeutics is a preclinical-stage oncology company developing transformative therapeutics to target drug-resistant cancers. Concarlo’s vision is to create a world of possibility and time, where cancer is a treatable, manageable, and survivable condition.
Concarlo is developing therapies to drug p27, the natural inhibitor of
CDK4/CDK6 and CDK2. The company is harnessing decades of research to target a unique cellular pathway to kill – not just stop – the growth of tumor cells. Concarlo is leveraging its deep understanding of this pathway to develop new treatments for a wide range of advanced and drug-resistant cancers.
Women Founded
Women Led
